SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline…Read More
Journey Medical Corporation Announces Data from Bioavailability Study of DFD29 Minocycline Hydrochloride Modified Release Capsules 40 mg vs Solodyn Minocycline Hydrochloride ExtendedRelease Tablets 105 mg
